ClinicalTrials.gg
Not yet recruitingNCT07751276Updated Aug 7, 2026

Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC

A Phase 2 interventional study of Neoadjuvant Finotonlimab Plus Chemotherapy and Surgery in Head and Neck Squamous Cell Carcinoma HNSCC, sponsored by Yanjie Zhang, MD. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Yanjie Zhang, MD · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This multicenter, randomized, open-label, parallel-controlled clinical trial aims to evaluate the efficacy and safety of surgery combined with postoperative chemoradiotherapy versus finotonlimab plus induction chemotherapy followed by postoperative finotonlimab maintenance therapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

02

Conditions studied

  • Head and Neck Squamous Cell Carcinoma HNSCC

Keywords

  • Stage II Head and Neck Squamous Cell Carcinoma
  • Neoadjuvant Chemoimmunotherapy
  • Anti-PD-1 Therapy
  • Finotonlimab
03

In context

Squamous Cell Carcinoma of Head and Neck

2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's planned enrollment of 142 is above the median of 48 across 1,654 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

Yanjie Zhang, MD is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years
  2. confirmed primary head and neck squamous cell carcinoma (excluding nasopharyngeal carcinoma)
  3. Clinical stage II (8th edition TNM staging), no distant , primary tumor resectable
  4. sccore 0-1
  5. No prior radiotherapy, chemotherapy, immunotherapy, or biological therapy for the current head and neck tumor
  6. Willing to undergo surgical treatment
  7. No significant to immunotherapy, radiotherapy, or chemotherapy
  8. Major organ function meets the following criteria: a) Hematologic: WBC ≥ 4.0 × 10⁹/L, ≥ 1.5 × 10⁹/L, ≥ 100 × 10⁹/L, ≥ 90 g/L (no blood transfusion or blood products, no G-CSF or other hematopoietic growth factors within 14 days); b) Biochemistry: serum albumin ≥ 3.0 g/dL (30 g/L), ≤ 1.5 × , and AST ≤ 2.5 × ULN, BUN and CRE ≤ 1.5 × ULN or endogenous ≥ 60 mL/min (Cockcroft-Gault formula); c) Adequate coagulation: defined as or PT ≤ 1.5 × ULN; if the subject is receiving anticoagulation therapy, PT within the intended therapeutic range of the anticoagulant is acceptable
  9. Both male and female subjects are eligible; women of must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and must agree to use effective during the study and for 2 months after the last dose of antibody. Male subjects with female partners of childbearing potential must agree to use effective contraception during the study and for 2 months after the last dose of anti-PD-1 antibody
  10. The subject voluntarily enrolls in this study, signs the form, demonstrates good compliance, and cooperates with follow-up

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with /PD-L1 antibodies, anti-PD-L2 antibodies, anti-CD137 antibodies, CTLA-4 antibodies, or other drugs/antibodies targeting T-cell co-stimulation or checkpoint pathways
  2. Active severe disease. Subjects in stable condition not requiring systemic therapy are eligible, such as type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, and skin conditions not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia)
  3. Congenital or acquired immunodeficiency (e.g., infection), active (HBV-DNA ≥ 10⁴ copies/mL), or (HCV antibody positive and HCV-RNA above the lower limit of detection)
  4. Known to the study drug or any of its , or history of severe allergic reaction to other monoclonal antibodies
  5. Within 6 months prior to randomization: myocardial infarction, severe/unstable angina, class ≥ 2 cardiac dysfunction, supraventricular or ventricular arrhythmias, or symptomatic congestive heart failure
  6. Receipt of a within 4 weeks prior to the first dose of study drug; inactivated influenza vaccine administered by injection is permitted, while intranasal live attenuated influenza vaccine is not permitted
  7. Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation
  8. Known history of psychotropic substance abuse or drug addiction
  9. Pregnant or lactating women
  10. Diagnosis of any other within 5 years prior to study entry, except for curatively treated localized cancers including basal cell carcinoma or squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma
  11. Any other severe physical or psychiatric illness or laboratory abnormality that may increase the risk of study participation, interfere with study results, or render the patient unsuitable for study participation in the opinion of the investigator
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (estimated)

Study arms

  • Active comparator
    Upfront Surgery

    Participants undergo upfront surgery. Based on postoperative pathological risk factors, participants may receive postoperative radiotherapy or concurrent chemoradiotherapy.

    Procedure: Surgery

  • Experimental
    Neoadjuvant Finotonlimab Plus Chemotherapy

    Participants receive two 3-week cycles of neoadjuvant finotonlimab plus nab-paclitaxel and carboplatin or cisplatin, followed by surgery. Postoperative radiotherapy or concurrent chemoradiotherapy may be given based on pathological risk factors. Participants also receive six 3-week cycles of postoperative finotonlimab maintenance therapy.

    Drug: Neoadjuvant Finotonlimab Plus Chemotherapy · Procedure: Surgery · Drug: Postoperative Finotonlimab Maintenance

Interventions

  • DrugNeoadjuvant Finotonlimab Plus Chemotherapy

    Drug page: FinotonlimabStudies of FinotonlimabFinotonlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants receive neoadjuvant finotonlimab 200 mg intravenously on Day 1, albumin-bound paclitaxel 100 mg/m² intravenously on Days 1, 8, and 15, and carboplatin at an area under the concentration-time curve of 4 intravenously on Day 1 of each 21-day cycle for 2 cycles before surgery. Cisplatin 75 mg/m² intravenously on Day 1 may be substituted for carboplatin.

  • ProcedureSurgery

    Participants undergo definitive surgery. Postoperative radiotherapy or concurrent chemoradiotherapy may be administered according to postoperative pathological risk factors.

  • DrugFinotonlimabStudies of FinotonlimabFinotonlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants receive postoperative finotonlimab 200 mg intravenously on Day 1 of each 21-day cycle for up to 6 cycles. Treatment begins 3 to 6 weeks after surgery or, for participants receiving postoperative radiotherapy or concurrent chemoradiotherapy, within 2 weeks after completion of radiotherapy.

06

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS)

    Event-free survival (EFS) is defined as the time from randomization to the first occurrence of disease recurrence or metastasis after surgery; disease progression according to RECIST version 1.1 that prevents definitive surgery during preoperative treatment or occurs in participants who do not undergo definitive surgery; a second primary malignancy; or death from any cause. Disease progression during preoperative treatment that does not prevent definitive surgery is not considered an EFS event. Failure to undergo definitive surgery for reasons other than disease progression is not itself considered an EFS event. Participants without an EFS event will be censored at the date of the last adequate disease assessment. EFS will be estimated using the Kaplan-Meier method. The planned primary EFS analysis will be performed after all participants have had the opportunity for at least 24 months of follow-up after randomization.

    Time frame: 2 years after randomization

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) is defined as the time from randomization to death from any cause. Participants without a documented death will be censored at the date they were last known to be alive. OS will be estimated using the Kaplan-Meier method. The planned primary OS analysis will be performed after all participants have had the opportunity for at least 24 months of follow-up after randomization.

    Time frame: 2 years after randomization

  2. Major Pathological Response (MPR) Rate

    The proportion of participants in the experimental-arm intention-to-treat population who achieve a major pathological response. MPR is defined as 10% or less residual viable tumor in the resected primary tumor and sampled regional lymph nodes, calculated as the area of residual viable tumor divided by the total tumor bed area.

    Time frame: Within 2 weeks after surgery

  3. Pathologic Complete Response (pCR) Rate

    The proportion of participants in the experimental-arm intention-to-treat population who achieve a pathologic complete response. pCR is defined as the absence of residual viable tumor cells in the resected primary tumor and all sampled regional lymph nodes.

    Time frame: Within 2 weeks after surgery

  4. 5-Year Overall Survival (OS)

    Overall survival (OS) is defined as the time from randomization to death from any cause. Participants without a documented death will be censored at the date they were last known to be alive or at 5 years after randomization, whichever occurs first. OS will be estimated using the Kaplan-Meier method.

    Time frame: 5 years after randomization

  5. 5-Year Event-Free Survival (EFS)

    Event-free survival (EFS) is defined as the time from randomization to the first occurrence of disease recurrence or metastasis after surgery; disease progression according to RECIST version 1.1 that prevents definitive surgery during preoperative treatment or occurs in participants who do not undergo definitive surgery; a second primary malignancy; or death from any cause. Disease progression during preoperative treatment that does not prevent definitive surgery is not considered an EFS event. Failure to undergo definitive surgery for reasons other than disease progression is not itself considered an EFS event. Participants without an EFS event will be censored at the date of the last adequate disease assessment or at 5 years after randomization, whichever occurs first. EFS will be estimated using the KaplanMeier method.

    Time frame: 5 years after randomization

  6. 2-Year Distant Metastasis-Free Survival (DMFS)

    Distant metastasis-free survival (DMFS) is defined as the time from randomization to the first occurrence of distant metastasis or death from any cause, whichever occurs first. Participants who remain alive and distant metastasis-free will be censored at the date of the last adequate disease assessment. DMFS will be estimated using the Kaplan-Meier method.

    Time frame: 2 years after randomization

  7. 5-Year Distant Metastasis-Free Survival (DMFS)

    Distant metastasis-free survival (DMFS) is defined as the time from randomization to the first occurrence of distant metastasis or death from any cause, whichever occurs first. Participants who remain alive and distant metastasis-free will be censored at the date of the last adequate disease assessment. DMFS will be estimated using the Kaplan-Meier method.

    Time frame: 5 years after randomization

  8. 2-Year Locoregional Recurrence-Free Survival (LRFS)

    Locoregional recurrence-free survival (LRFS) is defined as the time from randomization to the first occurrence of locoregional recurrence or death from any cause, whichever occurs first. Participants who remain alive and free of locoregional recurrence will be censored at the date of the last adequate disease assessment. LRFS will be estimated using the Kaplan-Meier method.

    Time frame: 2 years after randomization

  9. 5-Year Locoregional Recurrence-Free Survival (LRFS)

    Locoregional recurrence-free survival (LRFS) is defined as the time from randomization to the first occurrence of locoregional recurrence or death from any cause, whichever occurs first. Participants who remain alive and free of locoregional recurrence will be censored at the date of the last adequate disease assessment. LRFS will be estimated using the Kaplan-Meier method.

    Time frame: 5 years after randomization

  10. Incidence of Adverse Events

    The number and proportion of participants who experience adverse events, serious adverse events, Grade 3 or higher adverse events, treatment-related adverse events, and adverse events leading to treatment modification or discontinuation. Adverse events will be coded using MedDRA version 25.0 by preferred term and system organ class. Treatment-emergent adverse events are defined as adverse events occurring after initiation of the assigned study treatment.

    Time frame: From initiation of assigned treatment through 30 days after treatment completion or discontinuation; serious adverse events and adverse events of special interest through 90 days after treatment completion or discontinuation.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2029, 40 months later.

Of 298 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 40 months is below that.

Counting every sponsor, half of 365 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 7, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2032
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07751276
Lead sponsor
Yanjie Zhang, MD
Responsible party
Yanjie Zhang, MD (Professor and Chief Physician, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University) — Sponsor-investigator
First posted
Aug 7, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Aug 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finotonlimab

Start the discussion